OBJECTIVE: To probe into the potential mechanism of Huazhi Rougan Granules in the treatment of non-alcoholic fatty liver disease(NAFLD) based on network pharmacology and molecular docking. METHODS: The drug compound targets were screened by using the Traditional Chinese Medicine Systematic Pharmacology Database and Analysis Platform and the Encyclopedia of Chinese Medicine database, the disease targets of NAFLD were screened by using the GeneCards database and DigSee database, so that the related networks were constructed. Gene ontology function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed for the shared targets by using R language. Finally, the molecular docking verification of key compounds and core targets was conducted, and the results were visualized by using Pymol software. RESULTS: The predicted core compounds were quercetin, kaempferol, luteolin and wogonin, the core targets were signal transduction and activating transcription factor 3, JUN, interleukin-6, tumor necrosis factor, CXCL8, vascular endothelial growth factor A, epidermal growth factor, interleukin-1β, chemokine ligand 2 and TP53. The results of KEGG pathway enrichment analysis showed that the pathways were associated with infectious diseases, immune system, endocrine and metabolic diseases, such as the AGE-RAGE signaling pathway, human cytomegalovirus infection and other signaling pathways in diabetic complications. CONCLUSIONS: The results of this study have initially validated and predicted the mechanism of Huazhi Rougan granules in the treatment of NAFLD, which laid a good foundation for further insight into its mechanism of action. [ABSTRACT FROM AUTHOR]